
BIRAC CTN - Diabetology

Newsletter

Quarterly Newsletter: 10 (Jun 2023 - Aug 2023)

Introduction

The Clinical Trial Network (CTN) for Hospital Based Trial in Diabetology, a network of 7 hospitals across India has been established in terms of research facilities and are now open for new trials in Diabetology as a network.



The sites are approaching pharmaceutical industries for Clinical Trials in Diabetology in Network Mode

Content

Introduction Page 1

Journey so far Page 2

Recent Events Pages 3-14

Future plans, Upcoming Events Page 14


JOURNEY SO FAR


Events held: From 1st June 2023 to 31st August 2023

Diabetes Registry

The Hospital Based Multi Centric Diabetes Registry has captured baseline data of 23054 participants and follow up data of 470 participants as of 31st Aug 2023.

Registry Recruitment status





SAG Committee Meeting 4th July 2023



BIRAC Meeting in continuation to SAG Committee Meeting 19th July 2023

The points discussed:

- Ongoing Studies in Endocrinology Department Network Mode
- Publications and Presentations
- Planned Investigator Initiated Study In Network Mode
- Challenges at sites in getting clinical trials
- Future sustainability plan

ICLINSYMPOSIA 2023

28th July 2023

Conducted at M S Ramaiah Medical College and Hospitals

M S Ramaiah Medical College and Hospitals hosted "ICLINSYMPOSIA 2023" titled "Empowering Clinical Research" in collaboration with Infloclin consultancy and ISCR. All collaborating site within CTN Diabetology was part of the program.





ICLINSYMPOSIA 2023 28th July 2023

Conducted at M S Ramaiah Medical College and Hospitals



ICLINSYMPOSIA 2023

28th July 2023

Conducted at M S Ramaiah Medical College and Hospitals

Dr. Saurendra Das, Director of Medical Affairs, Hazlo Consultancy. He has over 25 years research experience in managing all phases of global and domestic clinical research projects of innovative healthcare products and cutting-edge technology medical devices. He has been involved in setting up 8 major healthcare and research organizations across India. He has successfully trained more than 10,000 investigators, physicians, dentists, CRC's & CRAs', other stakeholders including lab and pharmacy personnel and ethics committee members. He was in charge of the 4 sites which became the first clinical trial sites in India to be inspected by US FDA and of 4 sites which were inspected by EMA. He is into Digital health and digitization of clinical trial management.



Innovate In India i3 Mission

- · National Biopharma Mission under BIRAC, DBT
- · CHOORD (Consortia of Hospitals in Onco, Ophthal, Rheumat, Diabet)

Gokula Education Foundation Diabetology Network (7 sites)



ICLINSYMPOSIA - 2023

Dr. Saurendra Das, was one of the speaker for ICLINSYMPOSIA. During his session he briefed about BIRAC_CTN Diabetology and the importance of such networks for the clinical research industry.

Accomplishment

A. ONGOING STUDIES IN ENDOCRINOLOGY DEPART-MENT - NETWORK MODE

I. MSRMCH, BANGALORE & IPGMER, SSKM HOSPITAL, KOLKATA

Study Title	Sponsor
A Randomized, Controlled, Multicenter	Crinetics Pharmaceutical
Study to Evaluate the Safety and Efficacy	
of Paltusotine in Subjects with Non-	
pharmacologically Treated Acromegaly	

II. BMCRI, BANGALORE & IPGMER, SSKM HOSPITAL, KOLKATA

Study Title	Sponsor
A Master Protocol to Investigate the Effi-	Eli Lilly
cacy and Safety of XX Once weekly in	
Participants with Type 2 Diabetes Melli-	
tus who have Obesity or Overweight: A	
Randomized, Double-Blind, Placebo-	
Controlled Trial(TRIUMPH-2)	

B. FEASIBILITY IN NETWORK MODE

I. SGRDUHS, Amritsar & NIMS Medicity, Trivandrum

Study Title	Sponsor
A Prospective, Interventional, Multicen-	Square Pharmaceuticals Ltd.
ter, Post-marketing Clinical Study of An-	
sulin 30/70 Injection 100 IU/ml {Insulin	
Human (rDNA) 30/70 100 Injection} in	
the treatment of Diabetes Mellitus (DM)	

Accomplishment

B. FEASIBILITY IN NETWORK MODE

II. MSRMCH, Bangalore & IPGMER, SSKM Hospital, Kolkata


Study Title	Sponsor
The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with obesity and established cardiovascular disease	Novonordisk
Efficacy and safety of early initiation of oral semaglutide 50 mg and 25 mg once daily versus empagliflozin 25 mg once daily and versus metformin 2 g in treatment native patients with newly diagnosed type 2 diabetes and overweight or obesity	Novonordisk

Plan for Sustainability

- Approaching pharmaceutical industries for Clinical Trials in Diabetology in Network Mode
- Strengthening the social presence of the CTN Diabetology Network
- Diabetes Research India Diabetology Clinical Trial Network (Website)
- Shared Investigators Platform, Cognizant
- Registering the Sites in the CTN under India-International platforms, Clinical Networks and authorized Organisations
- Novonordisk Study Cardiometabolic Disorders

World Prediabetes Day Awareness Programme

at M S Ramaiah Medical College Hospital on 16th August 2023



Patient Awareness Program for Diabetes Patients Conducted at M S Ramaiah Medical College Hospital on 12th June 2023 and 18th August 2023





Patient Awareness Program for Diabetes Patients Conducted at SIMS Hospital, Chennai on

24th July 2023 and 2nd August 2023



Patient Awareness Program for Diabetes Patients & Fibro Scan for Obesity Patients Conducted at BMCRI, Bangalore on 9th August 2023



Patient Awareness Program for Diabetes Patients Conducted at SGRDUHS, Amritsar on 22nd August 2023



Patient Awareness Program for Diabetes Patients Conducted at IPGMER, Kolkata on 23rd August 2023





Meeting updates from

1st June 2023 - 31st August 2023



Future plans

- ⇒ Conduct of virtual quality management activity for baseline data (3%) and follow up data (3%) for all sites by Lead site
- ⇒ Preparation of third interim registry report

Upcoming events

⇒ BIRAC - Diabetology CTN PM Monthly meeting for the month of Sept 2023 will be held on 6th Sept 2023 @ 2:30 pm via Microsoft Teams